{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:02Z","timestamp":1787232542263,"version":"build-2736575974"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Irish Research Council (IRC) Government of Ireland Postgraduate Scholarship","award":["GOIPG\/2019\/4432"],"award-info":[{"award-number":["GOIPG\/2019\/4432"]}]},{"name":"ERASMUS+ Scholarship","award":["240\/E2023-24"],"award-info":[{"award-number":["240\/E2023-24"]}]},{"name":"Irish Health Research Board","award":["41897 and 58264"],"award-info":[{"award-number":["41897 and 58264"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      HIV-1 latency and persistence of viral reservoirs within memory CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells remain a fundamental obstacle to achieving a cure despite suppressive antiviral treatments. HIV-1 persistence is sustained by the dynamic interactions between viral regulatory mechanisms and the host cellular environment. At the intersection between immunometabolism and virology, the quiescent metabolic profile of resting CD4\n                      <jats:sup>+<\/jats:sup>\n                      \u2009T cells, defined as the balance between oxidative phosphorylation (OXPHOS) and aerobic glycolysis, supports the long-term maintenance of latent viral reservoirs. Existing \u201cShock and Kill\u201d strategies have shown limited clinical impact, partly due to the metabolic constraints that limit robust viral reactivation. Targeting metabolic junctions to overcome this barrier may provide a complementary therapeutic avenue.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We evaluated Zaprinast, a mitochondrial pyruvate carrier inhibitor (MPCi), for its capacity to reprogramme CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cell metabolism and promote latency reversal. Across multiple primary T-cell based models of HIV-1 latency, Zaprinast induced a moderate yet reproducible increase in HIV-1 gene expression and viral particle production, including in circulating reservoirs from antiretroviral-treated individuals cultured\n                      <jats:italic>ex vivo<\/jats:italic>\n                      . Metabolic profiling revealed a biphasic response: an initial, transient inhibition of mitochondrial respiration followed by a shift from an OXPHOS-dominant to a more glycolytic metabolic state, while maintaining mitochondrial function. This metabolic reprogramming of resting CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells by Zaprinast was reversible and did not impair cell viability, trigger non-specific T cell activation or proliferation, nor elevate reactive oxygen species levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These results highlight that selective targeting of the quiescent metabolic state in resting CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells can facilitate HIV-1 reactivation without compromising cellular integrity. This study identifies host metabolic reprogramming as a promising strategy to enhance latency reversal and complement existing cure strategies. Our work provides new insights into the importance of host metabolic states in governing viral persistence and underscores the translational potential of metabolic interventions in HIV-1 eradication research.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12977-026-00680-x","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:14:20Z","timestamp":1781334860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic reprogramming of CD4\u207a T cells by Zaprinast induces HIV-1 latency reversal ex vivo"],"prefix":"10.1186","volume":"23","author":[{"given":"V.","family":"De Masson d\u2019Autume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"LeDouce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dutilleul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Formiconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Angieladis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pilosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bendoumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Garcia","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Alalwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"McGinty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Valle-Casuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Macken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"S\u00e1ez-Ciri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. W. G.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. V.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"1","key":"680_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12977-024-00639-w","volume":"21","author":"U Mbonye","year":"2024","unstructured":"Mbonye U, Karn J. The cell biology of HIV-1 latency and rebound. Retrovirology. 2024;21(1):6.","journal-title":"Retrovirology"},{"key":"680_CR2","doi-asserted-by":"publisher","first-page":"115679","DOI":"10.1016\/j.bcp.2023.115679","volume":"214","author":"S Saeb","year":"2023","unstructured":"Saeb S, et al. Targeting and eradicating latent CNS reservoirs of HIV-1: Original strategies and new models. Biochem Pharmacol. 2023;214:115679.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"680_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jmp.12613","volume":"51","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Kim Y, Roche M, Lewin SR. The role of latency reversal in HIV cure strategies. J Med Primatol. 2022;51(5):278\u201383.","journal-title":"J Med Primatol"},{"key":"680_CR4","doi-asserted-by":"crossref","unstructured":"Pasternak AO, Rohr O, Van Lint C, Kula-Pacurar A. Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency. Front Cell Infect Microbiol, 2023. 13: 1190867.","DOI":"10.3389\/fcimb.2023.1190867"},{"issue":"1","key":"680_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev-virology-091919-103029","volume":"8","author":"A Rodari","year":"2021","unstructured":"Rodari A, Darcis G, Van Lint CM. The Current Status of Latency Reversing Agents for HIV-1 Remission. Annu Rev Virol. 2021;8(1):491\u2013514.","journal-title":"Annu Rev Virol"},{"key":"680_CR6","doi-asserted-by":"crossref","unstructured":"Ait-Ammar A et al. Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. Front Microbiol, 2020. 10:3060.","DOI":"10.3389\/fmicb.2019.03060"},{"issue":"1","key":"680_CR7","doi-asserted-by":"publisher","first-page":"16545","DOI":"10.1038\/s41598-024-67334-w","volume":"14","author":"T De La Tarazona","year":"2024","unstructured":"De La Tarazona T. Author Correction: High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells. Sci Rep. 2024;14(1):16545.","journal-title":"Sci Rep"},{"issue":"11","key":"680_CR8","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.4049\/jimmunol.1600120","volume":"196","author":"CS Palmer","year":"2016","unstructured":"Palmer CS, et al. Emerging Role and Characterization of Immunometabolism: Relevance to HIV Pathogenesis, Serious Non-AIDS Events, and a Cure. J Immunol. 2016;196(11):4437\u201344.","journal-title":"J Immunol"},{"key":"680_CR9","doi-asserted-by":"publisher","first-page":"103985","DOI":"10.1016\/j.ebiom.2022.103985","volume":"79","author":"R Verdikt","year":"2022","unstructured":"Verdikt R, et al. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine. 2022;79:103985.","journal-title":"EBioMedicine"},{"key":"680_CR10","doi-asserted-by":"publisher","first-page":"1068436","DOI":"10.3389\/fcimb.2022.1068436","volume":"12","author":"JM Crater","year":"2022","unstructured":"Crater JM, Nixon DF. Furler O\u2019Brien, HIV-1 replication and latency are balanced by mTOR-driven cell metabolism. Front Cell Infect Microbiol. 2022;12:1068436.","journal-title":"Front Cell Infect Microbiol"},{"key":"680_CR11","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Ciri\u00f3n A, Sereti I. Immunometabolism and HIV-1 pathogenesis: food for thought. Nature Reviews. Immunology; 2020. 21(1):5-19.","DOI":"10.1038\/s41577-020-0381-7"},{"issue":"4","key":"680_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41590-021-00898-1","volume":"22","author":"H Guo","year":"2021","unstructured":"Guo H, et al. Multi-omics analyses reveal that HIV-1 alters CD4(+) T cell immunometabolism to fuel virus replication. Nat Immunol. 2021;22(4):423\u201333.","journal-title":"Nat Immunol"},{"issue":"3","key":"680_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/QAD.0000000000000128","volume":"28","author":"CS Palmer","year":"2014","unstructured":"Palmer CS, et al. Increased glucose metabolic activity is associated with CD4\u2009+\u2009T-cell activation and depletion during chronic HIV infection. AIDS. 2014;28(3):297\u2013309.","journal-title":"AIDS"},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"843242","DOI":"10.3389\/fimmu.2022.843242","volume":"13","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zheng X, Yang W. The Role of Metabolic Dysfunction in T-Cell Exhaustion During Chronic Viral Infection. Front Immunol. 2022;13:843242.","journal-title":"Front Immunol"},{"issue":"3","key":"680_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmet.2018.11.015","volume":"29","author":"JC Valle-Casuso","year":"2019","unstructured":"Valle-Casuso JC, et al. Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4\u2009+\u2009T Cells and Offers an Opportunity to Tackle Infection. Cell Metabol. 2019;29(3):611\u2013e6265.","journal-title":"Cell Metabol"},{"issue":"7","key":"680_CR16","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1073\/pnas.1121427109","volume":"109","author":"S Loisel-Meyer","year":"2012","unstructured":"Loisel-Meyer S, et al. Glut1-mediated glucose transport regulates HIV infection. Proc Natl Acad Sci USA. 2012;109(7):2549\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"680_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00001","volume":"6","author":"CS Palmer","year":"2015","unstructured":"Palmer CS, et al. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol. 2015;6:1.","journal-title":"Front Immunol"},{"issue":"7","key":"680_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s42255-019-0084-1","volume":"1","author":"I Clerc","year":"2019","unstructured":"Clerc I, et al. Entry of glucose- and glutamine-derived carbons into the citric acid cycle supports early steps of HIV-1 infection in CD4 T cells. Nat Metabolism. 2019;1(7):717\u201330.","journal-title":"Nat Metabolism"},{"issue":"11","key":"680_CR19","doi-asserted-by":"publisher","first-page":"e48702","DOI":"10.1371\/journal.pone.0048702","volume":"7","author":"MA Jarboui","year":"2012","unstructured":"Jarboui MA, et al. Nucleolar protein trafficking in response to HIV-1 Tat: rewiring the nucleolus. PLoS ONE. 2012;7(11):e48702.","journal-title":"PLoS ONE"},{"key":"680_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1742-4690-6-47","volume":"6","author":"VW Gautier","year":"2009","unstructured":"Gautier VW, et al. In vitro nuclear interactome of the HIV-1 Tat protein. Retrovirology. 2009;6:47.","journal-title":"Retrovirology"},{"issue":"7","key":"680_CR21","doi-asserted-by":"publisher","first-page":"e68376","DOI":"10.1371\/journal.pone.0068376","volume":"8","author":"CA Barrero","year":"2013","unstructured":"Barrero CA, et al. HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis. PLoS ONE. 2013;8(7):e68376.","journal-title":"PLoS ONE"},{"key":"680_CR22","doi-asserted-by":"crossref","unstructured":"Planas D et al. HIV-1 selectively targets gut-homing CCR6\u2009+\u2009CD4+ T cells via mTOR-dependent mechanisms. JCI Insight, 2017. 2(15):e93230.","DOI":"10.1172\/jci.insight.93230"},{"issue":"12","key":"680_CR23","doi-asserted-by":"publisher","first-page":"107810","DOI":"10.1016\/j.celrep.2020.107810","volume":"31","author":"HE Taylor","year":"2020","unstructured":"Taylor HE, et al. mTOR Overcomes Multiple Metabolic Restrictions to Enable HIV-1 Reverse Transcription and Intracellular Transport. Cell Rep. 2020;31(12):107810.","journal-title":"Cell Rep"},{"issue":"30","key":"680_CR24","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.1073\/pnas.1511144112","volume":"112","author":"A Heredia","year":"2015","unstructured":"Heredia A, et al. Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proc Natl Acad Sci U S A. 2015;112(30):9412\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"680_CR25","doi-asserted-by":"publisher","first-page":"110670","DOI":"10.1016\/j.isci.2024.110670","volume":"27","author":"A Fert","year":"2024","unstructured":"Fert A, et al. Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies. iScience. 2024;27(9):110670.","journal-title":"iScience"},{"key":"680_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","volume":"36","author":"RIK Geltink","year":"2018","unstructured":"Geltink RIK, Kyle RL, Pearce EL. Unraveling the Complex Interplay Between T Cell Metabolism and Function. Annu Rev Immunol. 2018;36:461\u201388.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"680_CR27","doi-asserted-by":"publisher","first-page":"e13901","DOI":"10.15252\/emmm.202013901","volume":"13","author":"IL Shytaj","year":"2021","unstructured":"Shytaj IL, et al. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. EMBO Mol Med. 2021;13(8):e13901.","journal-title":"EMBO Mol Med"},{"issue":"10","key":"680_CR28","doi-asserted-by":"publisher","first-page":"e0286436","DOI":"10.1371\/journal.pone.0286436","volume":"18","author":"M Akiso","year":"2023","unstructured":"Akiso M, et al. Metabolic and mitochondrial dysregulation in CD4\u2009+\u2009T cells from HIV-positive women on combination anti-retroviral therapy. PLoS ONE. 2023;18(10):e0286436.","journal-title":"PLoS ONE"},{"issue":"10","key":"680_CR29","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41564-025-02128-y","volume":"10","author":"LM Plasek Hegde","year":"2025","unstructured":"Plasek Hegde LM, et al. HIV infection reprogrammes CD4\u2009+\u2009T cells for quiescence and entry into proviral latency. Nat Microbiol. 2025;10(10):2454\u201371.","journal-title":"Nat Microbiol"},{"issue":"10","key":"680_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41590-025-02282-9","volume":"26","author":"Z Li","year":"2025","unstructured":"Li Z, Ott M. HIV-induced T cell quiescence and the origins of viral latency. Nat Immunol. 2025;26(10):1633\u20134.","journal-title":"Nat Immunol"},{"issue":"5","key":"680_CR31","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2023.03.010","volume":"56","author":"S Mutascio","year":"2023","unstructured":"Mutascio S, et al. CD8(+) T cells promote HIV latency by remodeling CD4(+) T cell metabolism to enhance their survival, quiescence, and stemness. Immunity. 2023;56(5):1132\u2013e11476.","journal-title":"Immunity"},{"issue":"8","key":"680_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins DR, Gaiha GD, Walker BD. CD8(+) T cells in HIV control, cure and prevention. Nat Rev Immunol. 2020;20(8):471\u201382.","journal-title":"Nat Rev Immunol"},{"key":"680_CR33","doi-asserted-by":"crossref","unstructured":"Routy J-P et al. Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. BMJ Open, 2019. 9(4):e028444.","DOI":"10.1136\/bmjopen-2018-028444"},{"key":"680_CR34","doi-asserted-by":"publisher","first-page":"103270","DOI":"10.1016\/j.ebiom.2021.103270","volume":"65","author":"D Planas","year":"2021","unstructured":"Planas D, et al. LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine. 2021;65:103270.","journal-title":"EBioMedicine"},{"issue":"5","key":"680_CR35","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/ajt.16244","volume":"21","author":"TJ Henrich","year":"2021","unstructured":"Henrich TJ, et al. Everolimus, an mTORC1\/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transpl. 2021;21(5):1765\u201379.","journal-title":"Am J Transpl"},{"issue":"1","key":"680_CR36","doi-asserted-by":"publisher","first-page":"E33","DOI":"10.1152\/ajpendo.00074.2022","volume":"323","author":"NKH Yiew","year":"2022","unstructured":"Yiew NKH, Finck BN. The mitochondrial pyruvate carrier at the crossroads of intermediary metabolism. Am J Physiol Endocrinol Metab. 2022;323(1):E33\u201352.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"680_CR37","doi-asserted-by":"publisher","first-page":"e49634","DOI":"10.15252\/embr.201949634","volume":"21","author":"M Veliova","year":"2020","unstructured":"Veliova M, et al. Blocking mitochondrial pyruvate import in brown adipocytes induces energy wasting via lipid cycling. EMBO Rep. 2020;21(12):e49634.","journal-title":"EMBO Rep"},{"issue":"50","key":"680_CR38","doi-asserted-by":"publisher","first-page":"36129","DOI":"10.1074\/jbc.M113.507285","volume":"288","author":"J Du","year":"2013","unstructured":"Du J, et al. Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J Biol Chem. 2013;288(50):36129\u201340.","journal-title":"J Biol Chem"},{"issue":"35","key":"680_CR39","doi-asserted-by":"publisher","first-page":"37758","DOI":"10.18632\/oncotarget.5386","volume":"6","author":"Y Zhong","year":"2015","unstructured":"Zhong Y, et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget. 2015;6(35):37758\u201369.","journal-title":"Oncotarget"},{"issue":"9","key":"680_CR40","first-page":"1315","volume":"19","author":"H Xu","year":"2022","unstructured":"Xu H, et al. Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy. Cancer Biol Med. 2022;19(9):1315\u201333.","journal-title":"Cancer Biol Med"},{"key":"680_CR41","doi-asserted-by":"publisher","first-page":"101469","DOI":"10.1016\/j.molmet.2022.101469","volume":"60","author":"S Tavoulari","year":"2022","unstructured":"Tavoulari S, et al. Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer. Mol Metab. 2022;60:101469.","journal-title":"Mol Metab"},{"issue":"4","key":"680_CR42","doi-asserted-by":"publisher","first-page":"e14016","DOI":"10.1111\/apha.14016","volume":"238","author":"S Tavoulari","year":"2023","unstructured":"Tavoulari S, Sichrovsky M, Kunji ERS. Fifty years of the mitochondrial pyruvate carrier: New insights into its structure, function, and inhibition. Acta Physiol (Oxf). 2023;238(4):e14016.","journal-title":"Acta Physiol (Oxf)"},{"key":"680_CR43","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.molmet.2023.101694","volume":"70","author":"D Ferguson","year":"2023","unstructured":"Ferguson D, et al. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism. Mol Metab. 2023;70:101694.","journal-title":"Mol Metab"},{"issue":"2","key":"680_CR44","doi-asserted-by":"publisher","first-page":"101554","DOI":"10.1016\/j.jbc.2021.101554","volume":"298","author":"WT Hodges","year":"2022","unstructured":"Hodges WT, et al. Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice. J Biol Chem. 2022;298(2):101554.","journal-title":"J Biol Chem"},{"issue":"3","key":"680_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molcel.2014.09.024","volume":"56","author":"NM Vacanti","year":"2014","unstructured":"Vacanti NM, et al. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell. 2014;56(3):425\u201335.","journal-title":"Mol Cell"},{"issue":"5","key":"680_CR46","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cmet.2022.03.013","volume":"34","author":"M Wenes","year":"2022","unstructured":"Wenes M, et al. The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. Cell Metab. 2022;34(5):731\u2013e7469.","journal-title":"Cell Metab"},{"issue":"2","key":"680_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/aid.2015.0106","volume":"32","author":"LJ Martins","year":"2016","unstructured":"Martins LJ, et al. Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses. 2016;32(2):187\u201393.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"680_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/aid.2008.0191","volume":"25","author":"NM Archin","year":"2009","unstructured":"Archin NM, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009;25(2):207\u201312.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"680_CR49","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1172\/JCI92684","volume":"127","author":"NM Archin","year":"2017","unstructured":"Archin NM, et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J Clin Investig. 2017;127(8):3126\u201335.","journal-title":"J Clin Investig"},{"key":"680_CR50","doi-asserted-by":"crossref","unstructured":"Brogdon J et al. In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. Sci Rep, 2016. 6.","DOI":"10.1038\/srep39032"},{"key":"680_CR51","doi-asserted-by":"crossref","unstructured":"Dorman A et al. Nuclear retention of unspliced HIV-1 RNA as a reversible post-transcriptional block in latency. Nat Commun, 2025. 16(1): 2078.","DOI":"10.1038\/s41467-025-57290-y"},{"issue":"9","key":"680_CR52","doi-asserted-by":"publisher","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS Sogaard","year":"2015","unstructured":"Sogaard OS, et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog. 2015;11(9):e1005142.","journal-title":"PLoS Pathog"},{"key":"680_CR53","doi-asserted-by":"publisher","first-page":"103241","DOI":"10.1016\/j.ebiom.2021.103241","volume":"65","author":"JM Zerbato","year":"2021","unstructured":"Zerbato JM, et al. Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. EBioMedicine. 2021;65:103241.","journal-title":"EBioMedicine"},{"key":"680_CR54","doi-asserted-by":"crossref","unstructured":"Pasternak AO et al. Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. JCI Insight, 2020. 5(6) e134196.","DOI":"10.1172\/jci.insight.134196"},{"issue":"1","key":"680_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12977-018-0397-2","volume":"15","author":"AO Pasternak","year":"2018","unstructured":"Pasternak AO, Berkhout B. What do we measure when we measure cell-associated HIV RNA. Retrovirology. 2018;15(1):13.","journal-title":"Retrovirology"},{"issue":"2","key":"680_CR56","doi-asserted-by":"publisher","first-page":"e1008151","DOI":"10.1371\/journal.ppat.1008151","volume":"16","author":"RM Van der Sluis","year":"2020","unstructured":"Van der Sluis RM, et al. Diverse effects of interferon alpha on the establishment and reversal of HIV latency. PLoS Pathog. 2020;16(2):e1008151.","journal-title":"PLoS Pathog"},{"issue":"12","key":"680_CR57","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1128\/jvi.67.12.7423-7427.1993","volume":"67","author":"K Saksela","year":"1993","unstructured":"Saksela K, et al. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol. 1993;67(12):7423\u20137.","journal-title":"J Virol"},{"key":"680_CR58","doi-asserted-by":"crossref","unstructured":"Passaes CPB et al. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents. J Virol, 2017. 91(6):10-128..","DOI":"10.1128\/JVI.02296-16"},{"issue":"7","key":"680_CR59","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/nprot.2008.108","volume":"3","author":"MS Malnati","year":"2008","unstructured":"Malnati MS, et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc. 2008;3(7):1240\u20138.","journal-title":"Nat Protoc"},{"issue":"21","key":"680_CR60","doi-asserted-by":"publisher","first-page":"12385","DOI":"10.1128\/JVI.00609-14","volume":"88","author":"C Vandergeeten","year":"2014","unstructured":"Vandergeeten C, et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014;88(21):12385\u201396.","journal-title":"J Virol"},{"key":"680_CR61","unstructured":"Deeks SG, et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med; 2021."},{"issue":"3","key":"680_CR62","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.molcel.2014.09.025","volume":"56","author":"C Yang","year":"2014","unstructured":"Yang C, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014;56(3):414\u201324.","journal-title":"Mol Cell"},{"issue":"11","key":"680_CR63","doi-asserted-by":"publisher","first-page":"e1009060","DOI":"10.1371\/journal.ppat.1009060","volume":"16","author":"S Moron-Lopez","year":"2020","unstructured":"Moron-Lopez S, et al. Human splice factors contribute to latent HIV infection in primary cell models and blood CD4\u2009+\u2009T cells from ART-treated individuals. PLoS Pathog. 2020;16(11):e1009060.","journal-title":"PLoS Pathog"},{"key":"680_CR64","doi-asserted-by":"publisher","first-page":"855092","DOI":"10.3389\/fcimb.2022.855092","volume":"12","author":"R Crespo","year":"2022","unstructured":"Crespo R, Rao S, Mahmoudi T. HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency. Front Cell Infect Microbiol. 2022;12:855092.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"680_CR65","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/nar\/gkr857","volume":"40","author":"V Le Douce","year":"2012","unstructured":"Le Douce V, et al. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res. 2012;40(5):1904\u201315.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"680_CR66","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/j.1460-2075.1996.tb00449.x","volume":"15","author":"C Van Lint","year":"1996","unstructured":"Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 1996;15(5):1112\u201320.","journal-title":"EMBO J"},{"issue":"6090","key":"680_CR67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/science.1218099","volume":"337","author":"DK Bricker","year":"2012","unstructured":"Bricker DK, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science. 2012;337(6090):96\u2013100.","journal-title":"Science"},{"issue":"6090","key":"680_CR68","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1218530","volume":"337","author":"S Herzig","year":"2012","unstructured":"Herzig S, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012;337(6090):93\u20136.","journal-title":"Science"},{"issue":"1","key":"680_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","volume":"249","author":"GJ van der Windt","year":"2012","unstructured":"van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249(1):27\u201342.","journal-title":"Immunol Rev"},{"issue":"39","key":"680_CR70","doi-asserted-by":"publisher","first-page":"eabq0117","DOI":"10.1126\/sciadv.abq0117","volume":"8","author":"P Wei","year":"2022","unstructured":"Wei P, et al. Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. Sci Adv. 2022;8(39):eabq0117.","journal-title":"Sci Adv"},{"issue":"9","key":"680_CR71","doi-asserted-by":"publisher","first-page":"eadd5220","DOI":"10.1126\/sciadv.add5220","volume":"9","author":"F Petrelli","year":"2023","unstructured":"Petrelli F, et al. Mitochondrial pyruvate metabolism regulates the activation of quiescent adult neural stem cells. Sci Adv. 2023;9(9):eadd5220.","journal-title":"Sci Adv"},{"key":"680_CR72","doi-asserted-by":"crossref","unstructured":"Politte H, Maram L, Elgendy B. Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications. Biomolecules, 2025. 15(2).","DOI":"10.3390\/biom15020223"},{"issue":"7","key":"680_CR73","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/2159-8290.CD-13-0572","volume":"4","author":"A Elhammali","year":"2014","unstructured":"Elhammali A, et al. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov. 2014;4(7):828\u201339.","journal-title":"Cancer Discov"},{"issue":"4","key":"680_CR74","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s13311-021-01134-2","volume":"18","author":"FJ Sanz","year":"2021","unstructured":"Sanz FJ, et al. A High-Throughput Chemical Screen in DJ-1beta Mutant Flies Identifies Zaprinast as a Potential Parkinson\u2019s Disease Treatment. Neurotherapeutics. 2021;18(4):2565\u201378.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"680_CR75","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41467-018-03525-0","volume":"9","author":"C Corbet","year":"2018","unstructured":"Corbet C, et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018;9(1):1208.","journal-title":"Nat Commun"},{"issue":"14","key":"680_CR76","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1073\/pnas.1303360110","volume":"110","author":"AS Divakaruni","year":"2013","unstructured":"Divakaruni AS, et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A. 2013;110(14):5422\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"680_CR77","doi-asserted-by":"publisher","first-page":"200897","DOI":"10.1016\/j.omton.2024.200897","volume":"32","author":"M Wenes","year":"2024","unstructured":"Wenes M, et al. A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy. Mol Ther Oncol. 2024;32(4):200897.","journal-title":"Mol Ther Oncol"},{"issue":"3","key":"680_CR78","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/jnr.10102","volume":"67","author":"SH Choi","year":"2002","unstructured":"Choi SH, et al. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res. 2002;67(3):411\u201321.","journal-title":"J Neurosci Res"},{"issue":"21","key":"680_CR79","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1016\/j.febslet.2006.08.015","volume":"580","author":"Y Taniguchi","year":"2006","unstructured":"Taniguchi Y, Tonai-Kachi H, Shinjo K. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 2006;580(21):5003\u20138.","journal-title":"FEBS Lett"},{"key":"680_CR80","doi-asserted-by":"crossref","unstructured":"Yamashita Y, et al. A chemical proteomic probe for the mitochondrial pyruvate carrier complex. Angewandte Chemie. 2019.","DOI":"10.1002\/ange.201914391"},{"issue":"1","key":"680_CR81","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1038\/s41598-019-39898-5","volume":"9","author":"P Castellano","year":"2019","unstructured":"Castellano P, Prevedel L, Valdebenito S, Eugenin EA. HIV infection and latency induce a unique metabolic signature in human macrophages. Sci Rep. 2019;9(1):3941.","journal-title":"Sci Rep"},{"issue":"5","key":"680_CR82","doi-asserted-by":"publisher","first-page":"e0205323","DOI":"10.1128\/mbio.02053-23","volume":"14","author":"N Ikeogu","year":"2023","unstructured":"Ikeogu N, Ajibola O, Zayats R, Murooka TT. Identifying physiological tissue niches that support the HIV reservoir in T cells. mBio. 2023;14(5):e0205323.","journal-title":"mBio"},{"key":"680_CR83","doi-asserted-by":"crossref","unstructured":"Gallego-Cort\u00e9s A et al. Identification of the Inducible HIV reservoir in Tonsillar, Intestinal and Cervical Tissue Models of HIV Latency. bioRxiv, 2025. 2025.02.10.637439.","DOI":"10.1101\/2025.02.10.637439"},{"key":"680_CR84","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fcimb.2019.00362","volume":"9","author":"C Wallet","year":"2019","unstructured":"Wallet C, et al. Microglial Cells: The Main HIV-1 Reservoir in the Brain. Front Cell Infect Microbiol. 2019;9:362.","journal-title":"Front Cell Infect Microbiol"},{"key":"680_CR85","doi-asserted-by":"crossref","unstructured":"Corrado M, Pearce EL. Targeting memory T cell metabolism to improve immunity. J Clin Invest, 2022. 132(1).","DOI":"10.1172\/JCI148546"},{"issue":"1","key":"680_CR86","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"MD Buck","year":"2016","unstructured":"Buck MD, et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016;166(1):63\u201376.","journal-title":"Cell"},{"issue":"1","key":"680_CR87","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","volume":"36","author":"GJ van der Windt","year":"2012","unstructured":"van der Windt GJ, et al. Mitochondrial respiratory capacity is a critical regulator of CD8\u2009+\u2009T cell memory development. Immunity. 2012;36(1):68\u201378.","journal-title":"Immunity"},{"issue":"11","key":"680_CR88","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1128\/JVI.00006-13","volume":"87","author":"L Shan","year":"2013","unstructured":"Shan L, et al. A novel PCR assay for quantification of HIV-1 RNA. J Virol. 2013;87(11):6521\u20135.","journal-title":"J Virol"},{"issue":"9","key":"680_CR89","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"680_CR90","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ebiom.2015.06.019","volume":"2","author":"FA Procopio","year":"2015","unstructured":"Procopio FA, et al. A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015;2(8):874\u201383.","journal-title":"EBioMedicine"},{"key":"680_CR91","doi-asserted-by":"crossref","unstructured":"Ceriani C et al. Defining stable reference genes in HIV latency reversal experiments. J Virol, 2021. 95(11): 10-128","DOI":"10.1128\/JVI.02305-20"},{"issue":"1","key":"680_CR92","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12859-021-04306-1","volume":"22","author":"A Untergasser","year":"2021","unstructured":"Untergasser A, Ruijter JM, Benes V, van den Hoff MJB. Web-based LinRegPCR: application for the visualization and analysis of (RT)-qPCR amplification and melting data. BMC Bioinformatics. 2021;22(1):398.","journal-title":"BMC Bioinformatics"},{"issue":"15","key":"680_CR93","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.86.15.5974","volume":"86","author":"EJ Duh","year":"1989","unstructured":"Duh EJ, et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A. 1989;86(15):5974\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"680_CR94","unstructured":"Guoxiao Wang a, Rashmi Pillai N, Romero. and I. Agilent Technologies. Using the Agilent NovoCyte FlowCytometer for Immune Suspension Cell Normalization in Agilent Seahorse XF Assays. 2023. https:\/\/www.agilent.com\/cs\/library\/applications\/an-novocyte-seahorse-5994-6245en-agilent.pdf"},{"key":"680_CR95","unstructured":"MitoXpress X. & pH-Xtra Data Visualization Tool. https:\/\/www.agilent.com\/en\/product\/cell-analysis\/real-time-cell-metabolic-analysis\/xf-software\/mitoxpress-xtra-ph-xtra-data-visualization-tool-740896"},{"key":"680_CR96","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/cptx.3","volume":"70","author":"J Hynes","year":"2016","unstructured":"Hynes J, Carey C, Will Y. Fluorescence-Based Microplate Assays for In Vitro Assessment of Mitochondrial Toxicity, Metabolic Perturbation, and Cellular Oxygenation. Curr Protoc Toxicol. 2016;70:2161\u201321630.","journal-title":"Curr Protoc Toxicol"},{"issue":"2","key":"680_CR97","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tiv.2012.11.002","volume":"27","author":"J Hynes","year":"2013","unstructured":"Hynes J, et al. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol Vitro. 2013;27(2):560\u20139.","journal-title":"Toxicol Vitro"},{"issue":"1","key":"680_CR98","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ab.2009.04.016","volume":"390","author":"J Hynes","year":"2009","unstructured":"Hynes J, et al. In vitro analysis of cell metabolism using a long-decay pH-sensitive lanthanide probe and extracellular acidification assay. Anal Biochem. 2009;390(1):21\u20138.","journal-title":"Anal Biochem"},{"issue":"11","key":"680_CR99","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1039\/c1ib00050k","volume":"3","author":"AV Zhdanov","year":"2011","unstructured":"Zhdanov AV, et al. Comparative bioenergetic assessment of transformed cells using a cell energy budget platform. Integr Biol (Camb). 2011;3(11):1135\u201342.","journal-title":"Integr Biol (Camb)"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12977-026-00680-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-026-00680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-026-00680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:02:46Z","timestamp":1787230966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12977-026-00680-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1186\/s12977-026-00680-x","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the UCD Human Research Ethics Committees (LS-LR-22-246 dAutume-Gautier). HIV-1 CURE study received ethic approvals (RS19-004, 1\/378\/1808) from the St Vincent\u2019s Hospital group Research Ethics Committee and the Misericordiae University Hospital and Mater Private Hospital Research Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants of the study have consented for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.F. has received consulting fees from Gilead, ViiV and Vidacare Ireland, and has been awarded a grant from Science Foundation Ireland outside the submitted work. E.d.B. has received consulting fees from Sanofi Pasteur and an honoraria\/travel grant from Pfizer. P.M. has received honoraria and\/or travel grants from Gilead Sciences, MSD, Astrazeneca, and ViiV Healthcare, and has been awarded grants by Science Foundation Ireland outside the submitted work. C.V.L. is an Associate Editor for Retrovirology and was not involved in the peer review of this article. The remaining authors declare that no competing interests exist. This does not alter our adherence to Springer Nature policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"10"}}